Abbott FreeStyle Libre Rio

The FreeStyle Libre Rio is Abbott's attempt to take continuous glucose monitoring out of the pharmacy queue and put it on the shelf. Cleared by the FDA in June 2024 alongside the consumer-focused Lingo sensor, Rio is aimed squarely at one group: adults over 18 with type 2 diabetes who don't use insulin and manage their condition through diet, exercise and lifestyle change. That's a population an RBC analyst pegs at roughly 24.5 million people in the US, and one that has historically been locked out of CGM by prescription requirements and insurance gatekeeping.

On paper it's a familiar package — a filament-based biosensor worn on the back of the upper arm, reading interstitial glucose and pushing results to a phone app or a dedicated reader, with no routine fingersticks. What sets it apart from the OTC competition is its 40-400 mg/dL measuring range, which Abbott positions as the first over-the-counter sensor able to actually capture severe hypo- and hyperglycemic excursions rather than quietly topping out. The FDA deemed it substantially equivalent to Abbott's prescription Libre systems, which is a meaningful credential for a device you can buy off a shelf.

There is one very large caveat: as of the most recent retailer information we have, Rio is still being described as an upcoming release rather than a product you can buy. Nearly two years after clearance, that is an awkward gap between announcement and availability.

Judged purely on its clearance specification, Libre Rio is a sensible, well-scoped product. Fifteen days of wear is a genuinely competitive figure and reduces both cost-per-day and the nuisance of frequent sensor changes. The wide measuring range matters more than it might sound: an OTC sensor that clips at the extremes is of limited use to someone trying to understand how far their glucose actually swings after a meal or during illness, and Rio's range removes that asterisk. Dual reader-and-app support is also a quietly good decision for an older, less smartphone-dependent audience than Abbott's wellness-oriented Lingo targets.

The problems are less about the hardware and more about everything we don't know. There is no published price, no subscription or per-sensor cost, no stated accuracy figure, no warm-up time, no confirmed app compatibility list and, most importantly, no product you can actually buy. A CGM's value for this audience is overwhelmingly a function of running cost — this is a group paying out of pocket by definition, with no insurance approval in the loop — and without that number any purchase recommendation would be guesswork. The narrow indication is also worth flagging as a limitation rather than a flaw: if you use insulin, or you're under 18, this isn't the device for you, and the OTC label should not be read as an invitation to self-manage complex diabetes without clinical input.

• Our rating reflects a device with a credible, thoughtfully targeted specification that we simply cannot recommend buying yet — because you can't.
• We'd revisit this assessment immediately on launch, with pricing and real-world accuracy data in hand.

In short: promising, credible, and frustratingly hypothetical. Treat this as a preview of something worth waiting for rather than a buying guide, and if you need glucose data today, look at what is actually on shelves.